Experimental immune therapy targets deadly childhood brain cancers
NCT ID NCT03334305
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times
Summary
This early-phase study tested whether a custom-made vaccine and special immune cells (T-cells) could be given safely to children with newly diagnosed high-grade gliomas, a very aggressive brain cancer. The treatment used the patient's own tumor to create a vaccine that would train their immune system to attack cancer cells. The study was stopped early, but it aimed to see if this approach could safely boost the body's natural defenses against the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Children's of Alabama at UAB
Birmingham, Alabama, 35233, United States
-
UF Health Shands Children's Hospital
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.